心力衰竭标志物研究进展  

Biomarkers of heart failure

作　　者：徐晓燕 王建茹 邢作英[2] 朱明军[2] 王永霞[2] XU Xiao-yan;WANG Jian-ru;XING Zuo-ying;ZHU Ming-j un;WANG Yong-xia(Henan University of Traditional Chinese Medicine,Zhengzhou,Henan 450000,China;Department of Cardiovascular Medicine,the First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou,Henan 450000,China)

机构地区：[1]河南中医药大学,河南郑州450000 [2]河南中医药大学第一附属医院心血管病科,河南郑州450000

出　　处：《中华实用诊断与治疗杂志》2021年第6期565-568,共4页Journal of Chinese Practical Diagnosis and Therapy

基　　金：国家重点研发计划项目(2018YFC1707402);国家自然科学基金(81102698,81803944)。

摘　　要：心力衰竭是临床常见危重症,其过程涉及心肌损伤、心脏前后负荷增加、神经内分泌机制及炎性反应等。在心力衰竭的病理生理过程中产生了一系列生物标志物,心力衰竭标志物在心力衰竭的诊断、治疗和预后中发挥重要作用,有助于明确诊断、制定治疗方案和评估预后。利钠肽是心力衰竭标志物,但其存在自身的局限性,虽然新型心力衰竭标志物不断问世,但新的生物标志物在临床应用中仍有待不断完善。本文就心力衰竭标志物的研究进展作一综述。Heart failure is a common clinical critical disease,and its process involves myocardial injury,increased cardiac pre-and after-load,neuroendocrine mechanism,inflammatory response,etc.In the pathophysiological process of heart failure,a series of biomarkers are produced,and the heart failure markers play an important role in the diagnosis,treatment and prognosis assessment of heart failure,and contributes to the diagnosis clarifying,therapy plan formulation and the prognosis assessment.Natriuretic peptide is a marker of heart failure,but it has its own limitations.Although new biomarkers of heart failure continue to emerge,some of them need to be improved in clinical studies.This paper reviews the research progress of heart failure markers.

关 键 词：心力衰竭 生物标志物 预后评估 

分 类 号：R541.6[医药卫生—心血管疾病]